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Amikacin clearance can be increased in burn injury, which is often complicated by renal insufficiency. Little
is known about the impact of renal replacement therapies, such as continuous venovenous hemofiltration
(CVVH), on amikacin pharmacokinetics. We retrospectively examined the clinical pharmacokinetics, bacteri-
ology, and clinical outcomes of 60 burn patients given 15 mg/kg of body weight of amikacin in single daily doses.
Twelve were treated with concurrent CVVH therapy, and 48 were not. The pharmacodynamic target of >10 for
the maximum concentration of drug in serum divided by the MIC (Cmax/MIC) was achieved in only 8.5% of
patients, with a small reduction of Cmax in patients receiving CVVH and no difference in amikacin clearance.
Mortality and burn size were greater in patients who received CVVH. Overall, 172 Gram-negative isolates were
recovered from the blood cultures of 39 patients, with amikacin MIC data available for 82 isolates from 24
patients. A 10,000-patient Monte Carlo simulation was conducted incorporating pharmacokinetic and MIC
data from these patients. The cumulative fraction of response (CFR) was similar in CVVH and non-CVVH
patients. The CFR rates were not significantly improved by a theoretical 20 mg/kg amikacin dose. Overall,
CVVH did not appear to have a major impact on amikacin serum concentrations. The low pharmacodynamic
target attainment appears to be primarily due to higher amikacin MICs rather than more rapid clearance of
amikacin related to CVVH therapy.
Aminoglycosides are an important therapeutic option in crit-
ically ill patients with sepsis, and achieving a pharmacodynamic
target of 8 to 10 for the maximum concentration of drug in
serum divided by the MIC (Cmax/MIC) is recommended (14,
16). While aminoglycoside therapy has traditionally been given
in multiple daily doses, limited clinical evidence supports once-
daily maintenance dosing of 15 mg/kg of body weight for ami-
kacin and offers advantages in cost and convenience (9, 12).
However, aminoglycoside clearance can be enhanced in criti-
cally ill patients and patients with burn injury (8, 19, 21),
making this target more difficult to achieve. Increased amika-
cin doses could therefore be required in this population to
ensure clinical efficacy.
In our burn intensive care unit (ICU), we have observed that
patients with severe burn injury often develop clinical sepsis or
septic shock along with acute kidney injury, leading to concur-
rent antimicrobial and renal replacement therapies. Continu-
ous venovenous hemofiltration (CVVH) is most often used
since data from our center indicate a survival advantage over
historical controls who largely did not receive any form of renal
replacement (4, 5). However, the clinical impact of CVVH
therapy on aminoglycoside pharmacokinetics in burn patients
is uncertain. We therefore conducted a Monte Carlo simula-
tion using pharmacokinetic and MIC data from burn patients
to determine whether CVVH compromised our ability to
achieve a Cmax/MIC of 8 to 10 using standard once-daily
amikacin doses of 15 mg/kg.
MATERIALS AND METHODS
Clinical data. We reviewed the medical records of patients admitted to the
burn ICU of the United States Army Institute for Surgical Research (USAISR)
from 2006 to 2009. Patients were included if they received single daily amikacin
doses of approximately 15 mg/kg. Patients were excluded if they were less than
18 years of age, pregnant, admitted for reasons other than a primary thermal
burn injury, admitted within 72 h of the burn injury, or lacked sufficient amikacin
serum concentrations to calculate pharmacokinetic parameters. Patients admit-
ted after 72 h from the injury were included to ensure that pharmacokinetic
measurements would take place in the second phase of burn injury, which is
characterized by a hypermetabolic state. Amikacin doses, amikacin serum con-
centrations, CVVH treatment parameters, age, sex, and total body surface area
burned (TBSA) were recorded. The study was approved by the Institutional
Review Board.
Pharmacokinetic data. Amikacin serum concentrations were determined after
the first dose in the course of routine clinical care by the automated fluorescence
polarimetry method of the clinical laboratory. Each amikacin dose of approxi-
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mately 15 mg/kg was infused over 60 min. One postdistributional amikacin
concentration was drawn 1 h after the end of the infusion, and a second
amikacin concentration was obtained 8 to 12 h after the end of the infusion. The
patient was excluded if the second concentration was below the limit of detec-
tion. The first-dose pharmacokinetic parameters were calculated from these two
postdistributional concentrations using a one-compartment model by a modifi-
cation of the two-point method of Sawchuk and Zaske (18). The following
pharmacokinetic parameters were calculated for each patient: volume of distri-
bution of the central compartment (V), total clearance (CL), elimination half-life
(t1/2), area under the concentration-time curve over 24 h (AUC24), maximum
concentration in serum at the end of the infusion (Cmax), and concentration in
serum 24 h after the start of the infusion (Cmin). Pharmacy records were used to
obtain the timing and dose delivered; while nursing records were used to obtain
the time of sample collection. Each patient contributed data from a single dose
only once to the analysis.
Bacteriology. Amikacin MICs were determined for Gram-negative blood-
stream isolates using the Vitek 2 instrument (bioMe´rieux, Durham, NC), the
Phoenix instrument (Becton, Dickinson and Co., Franklin Lakes, NJ), or by
CLSI broth microdilution (6). Only those isolates obtained within 30 days before
or after amikacin therapeutic drug monitoring were reviewed for analysis.
CLSI interpretive criteria were utilized (6). Due to previously documented
inaccuracies with the Vitek 2 instrument (1), all Acinetobacter baumannii
isolates reported as susceptible to amikacin were confirmed by CLSI criteria
(7) according to the standard procedures of the clinical laboratory. For
Monte Carlo simulations, only MICs from the Phoenix instrument or broth
microdilution were used.
Monte Carlo simulations. We used Oracle Crystal Ball (Fusion Edition; Or-
acle USA, Inc., Redwood City, CA) to conduct multiple 10,000-subject Monte
Carlo simulations in order to determine the cumulative fraction of response
(CFR) for CVVH and non-CVVH patients against common Gram-negative
isolates. Cmax and AUC24 were modeled as a log-normal distribution using the
mean and standard deviation values derived from the study population. Custom
distributions were created for the Pseudomonas aeruginosa, Klebsiella pneu-
moniae, and A. baumannii isolates obtained from these patients. Pharmacoki-
netic and microbiologic data were integrated by dividing the Cmax and AUC24
probability distribution by the customized MIC distribution. Finally, the CFR
was determined, representing the combined probability of achieving Cmax/MIC
ratios of 8 and 10 and AUC24/MIC ratios of 100, 125, 150, and 175 (15). A 20
mg/kg dose of amikacin was also modeled in the same manner, and peaks were
estimated according to a 1-h infusion model.
Statistics. Proportions were compared using the chi-square distribution. The
Kolmogorov-Smirnoff test was used to check the continuous data for normality.
The means of continuous variables were compared using Student’s t test or the
Mann-Whitney U test as appropriate. The Wilcoxon rank-sum test was used to
compare serial creatinine values. All calculations were performed using SPSS for
Windows, version 16.0 (Chicago, IL).
RESULTS
Patient and infection characteristics. Sixty patients received
amikacin and had sufficient dosing and postinfusion data to
calculate pharmacokinetic parameters (Table 1). In-hospital
mortality was 35%, and 20 patients (51.3%) developed recur-
rent bacteremia after amikacin therapy. The majority of pa-
tients also received imipenem therapy. In the 48 patients who
did not receive CVVH, the mean and standard deviation for
serum creatinine were 1.0  0.3 mg/dl, and the mean creati-
nine clearance was 134  35 ml/min. Twelve patients were
simultaneously treated with CVVH. Of these, 10 patients were
treated using the Prismaflex system with an HF1400 polyaryle-
thersulfone (PAES) filter with a 1.4-m2 surface area (Gambro,
Lakewood, CO) and 2 were treated using the NxStage system
using a CAR-500 polyethersulfone (PES) filter with a 1.5-m2
surface area (NxStage Medical, Inc., Lawrence, MA). The
mean hemofiltration rate was 30.0  13.5 ml/kg/h (range, 10.6
to 55.6 ml/kg/h; median, 26.9 ml/kg/h). Clearance of amikacin
in CVVH recipients correlated with effluent rates (r  0.82).
One hundred seventy-two Gram-negative bloodstream iso-
lates were recovered from 39 patients within 30 days of the
amikacin dose. The predominant pathogens and amikacin
MIC data for 82 isolates are listed in Table 2. The other
isolates recovered included Stenotrophomonas maltophilia (11
isolates), Enterobacter aerogenes (9 isolates), Aeromonas hydro-
philia (6 isolates), Serratia marcescens (4 isolates), Escherichia
coli (3 isolates), Pantoea aglommerans (2 isolates), Haemophi-
lus influenzae (2 isolates), Serratia liquefaciens (2 isolates),
Klebsiella oxytoca (2 isolates), Proteus mirabilis (1 isolate), and
Enterobacter cloacae (1 isolate).
Pharmacokinetic data. Among those patients receiving
CVVH therapy, the amikacin Cmax and Cmin were significantly
lower and t1/2 was significantly longer (Table 1). Cmax was
noted to be significantly lower in association with more rapid
amikacin clearance and a larger volume of distribution as the
total body surface area burned (TBSA) exceeded 25% (Table
3). Considering the amikacin Cmax values in individual patients
relative to the MICs of bacteria recovered from them, the
target ratio of Cmax/MIC of 10 was satisfied for only 7 of 82
isolates (8.5%) collected from 7 different patients. The amika-
cin MICs of those isolates were 2 or 4 g/ml, in contrast to 8
g/ml for the remaining 75 isolates for which a Cmax/MIC ratio
of 10 was not satisfied.
Although the amikacin 15 mg/kg CFR given a Cmax/MIC of
10 was higher for patients not receiving CVVH, it was less
TABLE 1. Clinical and pharmacokinetic variables in burn patients
receiving amikacin
Without CVVH With CVVH P
Patients (No.) 48 12
Age (years) 37.9  20.2 28.3 8.4 0.11
TBSA (%) 38.4  21.8 74.0 15.9 0.001
Weight (kg) 94.9  20.7 83.3 20.9 0.10
Dose (mg) 1320.0  286.4 1158.3 357.9 0.17
Dose (mg/kg) 14.2 2.9 13.9  26 0.32
Cmax (g/ml) 36.3  10.2 29.1 14.5 0.05
Cmin (g/ml) 1.6  4.3 1.5  1.6 0.02
T1/2 (h) 4.75  5.24 5.49 2.35 0.003
CLamik (L/h) 7.8  3.7 8.8  8.9 0.37
AUC24 (mg  h/L) 239.0  262.7 214.8 113.8 0.52
V (L/kg) 0.60  1.01 0.84 1.06 0.36
Data are expressed as mean  SD, unless otherwise noted.
TBSA, % total body surface area burned; Cmax, maximum concentration;
Cmin, minimum concentration; k, rate constant of elimination; T1/2, half-life of
elimination; CL, amikacin clearance; AUC, area under the curve; V, apparent
volume of distribution.
TABLE 2. Gram-negative bacteria isolated in study patient
blood cultures
Bloodstream isolates (n  172) AmikacinSusceptibility
No. with
amikacin
MIC data
Amikacin
MIC50/
MIC90
Pseudomonas aeruginosa (55) 65.4% 26 16/64
Klebsiella pneumoniae (39) 65.5% 29 16/64
Acinetobacter baumannii (35) 39.1% 23 64/64
Other Enterobacteriaciae (43)
Stenotrophomonas maltophilia (11), Enterobacter aerogenes (9), Aeromonas hy-
drophilia (6), Serratia marcescens (4), E. coli (3), Pantoea aglommerans (2),
Haemophilus influenza (2), Serratia liquefaciens (2), Klebsiella oxytoca (2), Proteus
mirabilis (1), Enterobacter cloacae (1).
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than 50% for all isolates (Table 4). The CFRs remained less
than 60% for all isolates for a theoretical 20-mg/kg amikacin
dose using a lower threshold of Cmax/MIC of10. Amikacin 20
mg/kg CFRs were modeled for AUC24/MIC ratios of 100, 125,
and 150 since some studies have proposed these as potential
pharmacodynamic targets. CFRs were less than 15% for all
isolates at an AUC24/MIC of 100 and less than 5% for an
AUC24/MIC of 150 (data not shown).
DISCUSSION
Optimizing antimicrobial therapy is critical to ensure favor-
able clinical outcomes for life-threatening bacterial infections.
Previous studies have indicated that critical illness (17, 18) and
burn injury (21) are risk factors for inadequate aminoglycoside
dosing, even when 20 mg/kg of amikacin is administered as a
single daily dose (8). Based on previous data indicating signif-
icant survival advantages in burn patients who develop acute
renal insufficiency (4, 5), CVVH is often used for renal re-
placement therapy in our burn ICU. However, it is unclear
whether and to what extent CVVH therapy affects aminogly-
coside clearance and whether increased clearance might offset
the survival benefits of CVVH therapy. With this in mind, we
used data previously collected for clinical care to calculate
pharmacokinetic parameters for amikacin in severely burned
patients with and without exposure to concurrent CVVH ther-
apy and then used a Monte Carlo simulation to estimate the
CFR for these patients.
For aminoglycosides, which exert concentration-dependent
bactericidal activity, optimal efficacy is achieved when the
Cmax/MIC ratio is 8 to 10 (14, 16). Our data show that this
pharmacodynamic target was achieved infrequently, for only
8.5% of the isolates when using an average dose of 14.1 mg/kg.
Amikacin AUC24/MIC ratios of 150 were nearly unattain-
able using a 15-mg/kg dose. We did observe increased amika-
cin clearance with more extensive burns. Patients had lower
Cmax values due to large volumes of distribution and increased
clearance. This resulted in more difficult attainment of a Cmax/
MIC of 10. This finding agrees with prior observations of
increased amikacin clearance above a total body surface area
burned (TBSA) threshold of 15% (8).
The lack of pharmacodynamic target attainment in many of
our patients may also be due in part to high MICs of isolates
for which this target was not met. An isolate with a MIC of up
to 16 g/ml is considered susceptible by CLSI guidelines,
whereas the European susceptibility breakpoint is 8 g/ml.
In order to achieve a Cmax/MIC of 8 for CLSI susceptible
isolates, the amikacin peak would have to be unacceptably high
at 128 g/ml. Monte Carlo simulation data incorporating MIC
and pharmacokinetic data from within our burn ICU indicate
that a 20-mg/kg amikacin dose would not be sufficient to sig-
nificantly improve the CFR for accepted Cmax/MIC or AUC24/
MIC indices. While achieving a Cmax of 64 g/ml for isolates
with MICs of 8 g/ml may be considered safe, daily doses
greater than 35 mg/kg would likely be required given the V of
0.6 liters/kg in our burn patients. Such doses may increase the
likelihood of toxicity resulting from continuously elevated
trough concentrations. However, it is notable that once-daily
doses of amikacin as high as 50 mg/kg were recently used to
cure refractory P. aeruginosa infections in two patients, appar-
ently without toxic effects of therapy. In these patients, contin-
uous venovenous hemodiafiltration (CVVHDF) was used ad-
junctively to achieve low trough concentrations between doses
(13).
Interestingly, the amikacin serum concentrations, pharma-
cokinetic parameters, and CFRs in burn patients undergoing
CVVH were similar to those in non-CVVH patients. One
reason for this finding may be the greater relative %TBSA-to-
body weight ratio in the CVVH group. Indeed, our study and
others have demonstrated that a greater %TBSA may lead to
increased loss of aminoglycosides through the burn wound.
The prescribed CVVH doses and filter membranes used at our
institution may also result in amikacin clearances similar to
those in patients without acute kidney injury. These findings
are notable because a maximum empirical amikacin dose of 7.5
mg/kg every 24 h is recommended for nonburn critically ill
patients undergoing CVVH (10, 20). Following these empirical
dosing guidelines would likely result in peaks of less than 15
g/ml, which is a Cmax below the target for all isolates in our
study which had MICs of 2 g/ml. The 20-mg/kg modeled
amikacin dose would increase CFR in CVVH recipients, and
the Cmin would likely remain below 2 to 4 g/ml. One chal-
lenge to high-dose amikacin in CVVH patients would be un-
planned clotting of the continuous renal replacement therapy
(CRRT) circuit. If this were to occur shortly after the admin-
istration of a dose, a patient would be exposed to prolonged
concentrations of amikacin until CVVH could be resumed.
After comparing the high efficiency of amikacin drug removal
observed with CVVH in this study to the solute clearance
observed in other reports, we strongly recommend that amino-
glycoside dosing guidelines in patients undergoing CRRT be
institution specific. Using Monte Carlo simulations that incor-
porate these CRRT factors in addition to institution-specific
TABLE 3. Comparison of amikacin pharmacokinetic parameters
according to %TBSA
25%
TBSA
25%
TBSA P
Cmax (mean  SD, g/ml) 41.4  8.8 33.2 11.5 0.01
CLamik (mean  SD, L/h) 5.6  2.3 8.6 5.4 0.005
V (mean  SD, L/kg) 0.36  0.07 0.72 1.13 0.03
TABLE 4. Cumulative fraction of response (CFR) in burn patients
with or without concurrent CVVH therapy
Bloodstream isolates
15 mg/kga 20 mg/kga 20 mg/kgb
CVVH NoCVVH CVVH
No
CVVH CVVH
No
CVVH
A. baumannii 2% 3% 3% 4% 4% 4%
P. aeruginosa 20% 23% 23% 23% 24% 23%
K. pneumoniae 30% 36% 41% 42% 44% 43%
Other
Enterobacteriaceaec
36% 44% 50% 51% 53% 54%
a Cmax:MIC  10.
b Cmax:MIC  8.
c Includes Escherichia coli, Klebsiella spp., Proteus spp., Enterobacter spp. and
Serratia spp.
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MIC distributions should further guide empirical dosing rec-
ommendations.
This study has limitations. The number of patients receiving
concurrent CVVH therapy was small, reducing the sensitivity
for detecting an increase in amikacin clearance attributable to
CVVH (a type II error). While it would be interesting to
perform a population pharmacokinetic model on our amikacin
serum concentrations, the more precise estimates from such
modeling would be unlikely to significantly change the study
conclusions. We also described the amikacin pharmacokinetics
using a 1-compartment model, which would underestimate the
amikacin peak concentration. However, amikacin peak con-
centrations according to a two-compartment model would
probably remain less than 50 to 60 mg/liter, and few isolates
had MICs of less than 8 g/ml. Widely accepted pharmacody-
namic targets would still not be met in CVVH and non-CVVH
burn patients receiving once-daily amikacin doses of 15 mg/kg.
Pharmacokinetic calculations are exquisitely sensitive to the
elapsed time from the start and end of infusion, and we were
unable to verify the accuracy of the times recorded on labora-
tory samples. However, the resulting pharmacokinetic param-
eters are largely consistent with those of other studies (3, 8,
11). We deliberately used only bloodstream isolates for the
calculation of Cmax/MIC ratios, and thus, these findings cannot
be directly extrapolated to isolates recovered from other body
compartments. The evaluation of clinical pharmacodynamic
targets for amikacin in bacteremic patients is of significant
interest. However, many of the patients included in this study
received concomitant antimicrobial therapy.
In conclusion, critically ill burn patients are at increased risk
for inadequate dosing with amikacin. Although increased
clearance and volume of distribution may be contributing fac-
tors with larger surface area burns, the low CFR for a Cmax/
MIC of10 that we observed is also attributable to high MICs
among the recovered bacterial isolates. In addition, it appears
that high-dose daily aminoglycoside dosing may be appropriate
given the high efficiency of drug removal observed while re-
ceiving CVVH according to our institution’s CRRT prescrib-
ing practices. It should be noted that the CVVH recipients in
this study had TBSAs greater than 60%. As therapeutic op-
tions are progressively limited by increasing antimicrobial re-
sistance and rising MICs, new dosing strategies may be neces-
sary in order to deliver effective antimicrobial therapy to
critically ill and severely burned patients. It might be possible
to give higher amikacin doses and use CRRT to enhance drug
removal and minimize toxicity. Clinical trials are needed to
further assess this idea.
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